Clinical Trial Update: A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safety and efficacy of Pumitamig (BNT327) in patients with recurrent glioblastoma; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Pumitamig

Snippet

Sponsor: BioNTech SE | Conditions: Recurrent Glioblastoma | Phase 2 | Status: RECRUITING